

BIOSPECIFICS TECHNOLOGIES CORP

Form 4

August 19, 2008

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Vogel Jeffrey Kenneth

2. Issuer Name **and** Ticker or Trading  
Symbol  
BIOSPECIFICS TECHNOLOGIES  
CORP [BSTC.OB]

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

(Last) (First) (Middle)

1 MEADOW DRIVE

(Street)

3. Date of Earliest Transaction  
(Month/Day/Year)  
07/20/2007

\_\_\_\_ Director \_\_\_\_ 10% Owner  
\_\_\_\_ Officer (give title \_\_\_\_X\_\_\_\_ Other (specify  
below) below)  
5% Owner

4. If Amendment, Date Original  
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
\_X\_ Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting  
Person

LAWRENCE, NY 11559

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/20/2007		P	1,000 A \$ 4.6	497,041	I	See Footnote (1)
Common Stock	07/26/2007		P	500 A \$ 4.6	497,541	I	See Footnote (1)
Common Stock	07/26/2007		P	500 A \$ 4.65	498,041	I	See Footnote (1)
Common Stock	07/27/2007		P	500 A \$ 4.65	498,541	I	See Footnote

Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 4

								<u>(1)</u>
Common Stock	07/31/2007	P	500	A	\$ 4.65	499,041	I	See Footnote <u>(1)</u>
Common Stock	08/03/2007	P	500	A	\$ 4.72	499,541	I	See Footnote <u>(1)</u>
Common Stock	08/06/2007	P	500	A	\$ 4.75	500,041	I	See Footnote <u>(1)</u>
Common Stock	08/07/2007	P	2,000	A	\$ 4.95	502,041	I	See Footnote <u>(1)</u>
Common Stock	08/08/2007	P	1,000	A	\$ 5.1	503,041	I	See Footnote <u>(1)</u>
Common Stock	03/19/2008	P	500	A	\$ 10	503,541	I	See Footnote <u>(1)</u>
Common Stock	03/19/2008	P	1,500	A	\$ 10.1	505,041	I	See Footnote <u>(1)</u>
Common Stock	03/20/2008	P	500	A	\$ 10	505,541	I	See Footnote <u>(1)</u>
Common Stock	05/19/2008	P	350	A	\$ 10.25	505,891	I	See Footnote <u>(1)</u>
Common Stock	05/21/2008	P	140	A	\$ 12	506,031	I	See Footnote <u>(1)</u>
Common Stock	05/22/2008	P	1,500	A	\$ 12	507,531	I	See Footnote <u>(1)</u>
Common Stock	05/30/2008	P	700	A	\$ 12	508,231	I	See Footnote <u>(1)</u>
Common Stock	06/03/2008	P	1,200	A	\$ 11.25	509,431	I	See Footnote <u>(1)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not**

SEC 1474  
(9-02)

**required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 3)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

## Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
Vogel Jeffrey Kenneth 1 MEADOW DRIVE LAWRENCE, NY 11559	5% Owner

## Signatures

/s/ JEFFREY K.  
VOGEL 08/18/2008

\_\_Signature of Reporting Person Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Includes (i) 214,119 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by Bio Partners LP (Jeffrey Vogel is the sole shareholder and President of Bio Management Inc., the sole general partner of Bio Partners L.P.)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.